Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | GHSR | Q92847 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5998807 | 1.00 | MME (0.33) | MMEPPARABTN3A1KMT2ACTSL | |
| SCHEMBL5999105 | 0.90 | MME (0.32) | MMEPPARABTN3A1CTSLGHSR | |
| SCHEMBL5999102 | 0.90 | MME (0.32) | MMEPPARABTN3A1CTSLGHSR | |
| SCHEMBL6858198 | 0.90 | MME (0.32) | MMEPPARABTN3A1CTSLGHSR | |
| SCHEMBL6858195 | 0.90 | MME (0.32) | MMEPPARABTN3A1CTSLGHSR | |
| SCHEMBL5997770 | 0.87 | KMT2A (0.33) | MMEBTN3A1KMT2AHTT | |
| SCHEMBL5997778 | 0.87 | KMT2A (0.33) | MMEBTN3A1KMT2AHTT | |
| SCHEMBL5999132 | 0.85 | KMT2A (0.33) | BTN3A1KMT2AHTT | |
| SCHEMBL5999125 | 0.85 | KMT2A (0.33) | BTN3A1KMT2AHTT | |
| SCHEMBL14533022 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148218-B2 | Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors | NOVARTIS AG (CH) | 2006-12-12 | — | — | US | disclosed |
| US-20050080080-A1 | Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors | KINDER FREDERICK R (US) | 2005-04-14 | — | — | US | disclosed |
| US-6833367-B2 | A polyhydroxy-polymethyl-8-tridecenoic acid 8-lactone compounds, as antitumor agents, anticarcinogenic agents | NOVARTIS AC (CH) | 2004-12-21 | — | — | US | disclosed |
| US-20030153601-A1 | Certain substituted polyketides, pharmac eutical compositions containing them and their use in treating tumors | NOVARTIS AG (CH) | 2003-08-14 | — | — | US | disclosed |
| EP-1312608-A2 | Discodermolide analogues and their pharmaceutical use | Novartis AG (CH) | 2003-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153601-A1 | Certain substituted polyketides, pharmac eutical compositions containing them and their use in treating tumors | PBK, BCKDK, ETV6 | MME 2384/4885PPARA 1242/4885BTN3A1 3101/4885 |
| US-20050080080-A1 | Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors | PBK, HCCS, BCKDK | MME 3265/4885PPARA 1116/4885BTN3A1 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.